SCHEMBL21710229

SCHEMBL21710229

CCC(C)(C)N1Cc2c(N)cccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.41
TNF P01375 1/20 0.41
IL1B P01584 1/20 0.41
IKZF1 Q13422 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
PARP1 P09874 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ATM Q13315 4/20 0.36
USP2 O75604 2/20 0.36
KEAP1 Q14145 2/20 0.36
NFE2L2 Q16236 2/20 0.36
CYP1B1 Q16678 2/20 0.36
DPP4 P27487 1/20 0.35
MAPT P10636 4/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
KDM4E B2RXH2 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15784143 0.86 TNF (0.44) BRD4TNFIL1BIKZF1DDB1
SCHEMBL1949749 0.76 BRD4 (0.44) BRD4TNFIL1BIKZF1DDB1
SCHEMBL7849748 0.75 KDM4E (0.35) BRD4TNFIL1BIKZF1DDB1
SCHEMBL7857270 0.74 KDM4E (0.34) BRD4TNFIL1BIKZF1DDB1
SCHEMBL5906568 0.74 BRD4 (0.47) BRD4TNFIL1BIKZF1DDB1
SCHEMBL21591976 0.71 KDM4E (0.34) BRD4TNFIL1BIKZF1DDB1
SCHEMBL19934031 0.70 TNF (0.50) BRD4TNFIL1BIKZF1DDB1
SCHEMBL22625713 0.70 BRD4 (0.44) BRD4TNFIL1BIKZF1DDB1
SCHEMBL7952458 0.70 IDH1 (0.46) BRD4TNFIL1BIKZF1DDB1
SCHEMBL17577795 0.69 PARP1 (0.35) BRD4TNFIL1BIKZF1DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200046832-A1 COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE SANOFI (FR) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046832-A1 COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND LENALIDOMIDE CD38, BCL6, BCL6B BRD4 137/4885TNF 1157/4885IL1B 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.